Diane Weiser | SVP, Corporate Communications and Investor Relations |
Robert Blum | President And Chief Executive Officer |
Fady Malik | EVP, Research and Development |
Andrew Callos | EVP, Chief Commercial Officer |
Stuart Kupfer | SVP, Chief Medical Officer |
Robert Wong | VP, Chief Accounting Officer |
Ching Jaw | SVP, Chief Financial Officer |
Justin Kim | Oppenheimer |
Yasmeen Rahimi | Piper Sandler |
Michael Linden | Mizuho Group |
Joseph Pantginis | H.C. Wainwright |
Jason Butler | JMP Securities |
Charles Duncan | Cantor |
Rohit Bhasin | Needham & Company |
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Second Quarter 2022 Conference Call. At this time, I would like to inform you that this call is being recorded. All participants are in a listen-only mode. [Operator Instructions]. I would now like to turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations.